<DOC>
	<DOCNO>NCT00696735</DOCNO>
	<brief_summary>Follicular lymphoma subgroup B-cell non-Hodgkin lymphoma , account 15 % 30 % newly diagnose lymphomas.1-3 Median survival varies 5 10 year depend prognostic factor diagnosis response first-line therapy.4-6 Whatever treatment , plateau appear survival curve , virtually patient relapse ; follicular lymphoma ultimately progressive , fatal.2,3,5 No reference first-line treatment clearly define . One active therapy still doxorubicin-based chemotherapy without interferon.7-9 New therapeutic approach include purine analog anti-CD20 monoclonal antibody promise progressively include management lymphomas.2,3,10-13 The role high-dose therapy ( HDT ) salvage treatment patient relapse follicular lymphoma demonstrate author ; several report show superiority HDT follow autologous stem-cell transplantation , purge unpurged , compare conventional chemotherapy term relapse overall survival.14-18 Only report publish show HDT result first-line treatment poor-risk patient follicular lymphoma , result remain controversial.19-26 These data prompt French Groupe Ouest-Est de Leuc√©mies et Autres Maladies du Sang ( GOELAMS ) conduct prospective randomize trial use patient newly diagnose follicular lymphoma high tumor burden . A combined doxorubicin-based chemotherapy associate interferon compare front-line HDT follow purge autologous stem-cell transplantation .</brief_summary>
	<brief_title>High-Dose Therapy Treatment Patients With Follicular Lymphoma</brief_title>
	<detailed_description>Age 8-60 year old follicular lymphoma Not previously treat Stage II bulky , III IV An Arbor classification high tumor burden</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Age 1860 year old Follicular Lymphoma B , C D ( Working Formulation ) No previous treatment Seronegativity HIV ECOG performance status le 2 eligible autologous stemcell transplantation Stage II , III IV Ann Arbor Classification criterias high tumor burden Patient 's write informed consent Age le 18 year old 60 year old Other type lymphoma Stage le 3 IIIIV ( faible masse ) Seropositivity HIV Patients history another malignancy except basal cell skin cancer situ uterus cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Phase III study patient follicular lymphoma</keyword>
</DOC>